Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings
U.S. stocks tumbled: Nasdaq -4.5%, S&P 500 -3.3%, Dow -2.5%. Cardinal Health rose on strong results; AppLovin surged 32%, while Veracyte fell 55%.
Stocks · News reference
Needham Adjusts Veracyte Price Target to $46
Needham has maintained its 'Buy' rating on Veracyte while lowering the price target from $69 to $46.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is Veracyte Stock Sinking Thursday?
Veracyte (VCYT) stock tumbled 54% to a new 52-week low as weaker-than-expected Decipher Prostate test volumes overshadowed Q3 earnings beat.
Dow Surges 250 Points; US Weekly Jobless Claims Fall
U.S. stocks mixed: Dow +0.47%, Nasdaq -1.35%, S&P 500 -0.55%. Jobless claims fell to 189,000; oil and gold rose.
Leerink Partners Downgrades Veracyte to Market Perform
Leerink Partners has downgraded Veracyte from 'Outperform' to 'Market Perform' with a price target of $35.
Veracyte, Inc. Reports Financial Results for the Third Quarter 2026
Veracyte, Inc. announced its financial results for the third quarter ended September 30, 2026, highlighting strong profitability and cash generation.
Veracyte Q3 Adj. EPS $0.51 Beats $0.41 Estimate, Sales $151.754M Beat $147.439M Estimate